Welcome to our dedicated page for Akebia Therapeut news (Ticker: AKBA), a resource for investors and traders seeking the latest updates and insights on Akebia Therapeut stock.
Akebia Therapeutics, Inc. (Nasdaq: AKBA) is a biopharmaceutical company focused on therapies for people impacted by kidney disease, and its news flow reflects this specialization. Company announcements frequently highlight progress with Vafseo (vadadustat), a once-daily oral hypoxia-inducible factor prolyl hydroxylase inhibitor approved for the treatment of anemia due to chronic kidney disease (CKD) in adults on dialysis for at least three months. Updates include prescribing access among dialysis organizations, clinical trial data such as post-hoc analyses from the INNO2VATE trials, and real-world studies like VOICE and VOCAL that examine mortality, hospitalization, and dosing strategies.
News releases also cover Akebia’s rare kidney disease pipeline, including praliciguat and AKB-097. Investors can follow milestones such as the first patient dosed in a Phase 2 trial of praliciguat for biopsy-confirmed focal segmental glomerulosclerosis (FSGS), plans to evaluate praliciguat in other rare podocytopathies, and the planned Phase 2 basket study of AKB-097 across complement-mediated rare kidney diseases, including IgA nephropathy, lupus nephritis, and C3 glomerulopathy. Additional pipeline updates may involve AKB-9090, a HIF-PH inhibitor entering Phase 1 for acute kidney injury associated with cardiac surgery.
Akebia’s news stream also includes financial results, stock option inducement grants under Nasdaq Listing Rule 5635(c)(4), licensing and supply agreements such as amendments to its Vafseo license with Medice in Europe and certain other countries, and participation in healthcare and investor conferences. For investors tracking AKBA, this news page provides a centralized view of clinical, regulatory, commercial, and corporate developments that shape the company’s kidney disease franchise and pipeline trajectory.
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease treatments, has announced its participation in the upcoming H.C. Wainwright 4th Annual Kidney Virtual Conference. Chief Commercial Officer Nik Grund will engage in a Fireside Chat on Monday, July 14 at 10:00 AM EDT.
Investors and interested parties can access the presentation recording through the Investors section of Akebia's website at ir.akebia.com after the conference concludes.
Akebia Therapeutics (Nasdaq: AKBA), a biopharmaceutical company focused on kidney disease, has granted stock options to four newly-hired employees as employment inducements. The options total 141,800 shares of common stock with an exercise price of $3.64 per share, matching the closing price on June 30, 2025.
The options will vest over a four-year period, with 25% vesting after the first year and the remaining 75% vesting quarterly thereafter, contingent on continued employment. Each option has a 10-year term and follows Akebia's inducement award program guidelines and Nasdaq Listing Rule 5635(c)(4).
Akebia Therapeutics (NASDAQ: AKBA), a biopharmaceutical company focused on kidney disease treatments, has announced its participation in the upcoming Jefferies Global Healthcare Conference. The company's executive management will engage in a Fireside Chat scheduled for June 5, 2025, at 8:45 AM EDT in New York City. Investors and interested parties can access the webcast presentation through Akebia's investor relations website at ir.akebia.com after the conference concludes. The conference will run from June 3-5, 2025.
Akebia Therapeutics (AKBA) announced three upcoming poster presentations at the 62nd European Renal Association Congress 2025, taking place June 4-7 in Vienna. The presentations will focus on clinical data for vadadustat, their treatment for CKD-related anemia. Key presentations include: a cardiovascular safety analysis of vadadustat in dialysis patients presented by Dr. Glenn Chertow, a study on vadadustat's combination with ferric citrate, and real-world data comparing HIF-PH inhibitors with ESAs in non-dialysis CKD patients from a Japanese database study.
Akebia Therapeutics (NASDAQ: AKBA), a biopharmaceutical company focused on kidney disease treatments, has announced its participation in the upcoming H.C. Wainwright 3rd Annual BioConnect Investor Conference. The company's CEO John Butler and CCO Nik Grund will engage in a Fireside Chat on Tuesday, May 20, 2025, at 2:30 PM EDT at the Nasdaq Headquarters in New York City. Investors can access the presentation webcast through the "Investors" section of Akebia's website after the conference.
Akebia Therapeutics (NASDAQ: AKBA), a biopharmaceutical company focused on kidney disease treatments, has granted stock options to eight newly-hired employees. The inducement grants total 148,000 shares of common stock with an exercise price of $2.41 per share, matching the closing price on April 30, 2025. The options feature a 4-year vesting schedule with 25% vesting after the first year and the remaining 75% vesting quarterly thereafter. Each option has a 10-year term and is contingent on continued employment with Akebia.
Akebia Therapeutics (NASDAQ: AKBA) has announced it will release its first quarter 2025 financial results on Thursday, May 8, 2025, before market open. The company will host a conference call at 8:00 a.m. EDT on the same day to discuss the financial results and recent business highlights.
Participants are encouraged to dial in 15 minutes before the scheduled start time to ensure timely connection. A live webcast will be available through Akebia's Investors section website, with an online archive accessible afterward at ir.akebia.com.